Navigation Links
S&P: Leverage Tops Politics as Primary Credit Concern for U.S. Health Care Companies, Says S&P
Date:10/16/2007

NEW YORK, Oct. 16 /PRNewswire/ -- As the race to the 2008 elections heats up, nearly every presidential hopeful has offered a proposal for providing health care coverage.

"But when it comes to the already deteriorating credit quality of health care companies, the debt burden of industry players is a more overarching consideration than the rhetoric of presidential candidates making new health care proposals," said Standard & Poor's Ratings Services in a report published Oct. 12, 2007.

"For now, the more imminent operating challenges of aggressive debt- financed mergers and acquisitions, and volatile capital market conditions loom larger for the health care field than the longer term risk potential associated with U.S. presidential political platforms," said Standard & Poor's credit analyst Michael Kaplan in the report titled "Leverage -- Not Politics -- Is The Biggest Issue For Corporate Health Care Credit Strength."

In conjunction with this article, Standard & Poor's published several health care stories over the past week, ahead of its hot topics conference, "Politics And Leverage May Be Hazardous For Health Care," which will be held on Oct. 22, 2007.

For the full articles published on RatingsDirect:

-- "Increased Leverage And Health Care Reform Could Ail For-Profit

Hospital Credit"

-- "Top 10 Reasons Why States Are Central To Health Care Reform Efforts"

-- "Do Massachusetts Health Care Reform And California Proposals

Foreshadow A National Plan?"

-- "U.S. Health Care And Politics: As The Heat Rises, Can Big Pharma Stay

Insulated?"

-- "Clinical Labs, Distributors, And PBMs Share Financial Policy

Uncertainty And 'BBB' Ratings"

-- "Credit FAQ: Competitive Bidding's Impact On Durable Medical Equipment

Suppliers"

-- "Health Care Regulation -- Often A Curse, But Potentially, A Blessing"

The reports are available to subscribers of RatingsDirect, the real-time Web-based source for Standard & Poor's credit ratings, research, and risk analysis, at http://www.ratingsdirect.com. If you are not a RatingsDirect subscriber, you may purchase a copy of the report by calling (1) 212-438-9823 or sending an e-mail to research_request@standardandpoors.com. Ratings information can also be found on Standard & Poor's public Web site at http://www.standardandpoors.com; under Credit Ratings in the left navigation bar, select Find a Rating, then Credit Ratings Search. Members of the media may request a copy of this report by contacting the media representative provided.

About Standard & Poor's

Standard & Poor's, a division of The McGraw-Hill Companies (NYSE: MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 8,500 employees, including wholly owned affiliates, located in 21 countries, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.


'/>"/>
SOURCE Standard & Poor's
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Nominee Says That He Is Not Influenced By Politics
2. PRIMARY PULMONARY HYPERTENSION GENE DISCOVERED
3. Is caries in primary and permanent tooth related?
4. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
5. Shortage Of Funds In Primary Care Trust In UK
6. What Will Primary Care Look Like In England by 2015?
7. Primary Health Care MoU Signed on the Sidelines of the PBD
8. Primary Care centers to provide out patient treatment
9. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
10. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
11. Gene That Causes Metastasis of the Primary Tumor, Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Miami ... attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant ... will present its annual Global Symposium at the Fontainebleau Hotel located in Miami ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, ... neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announced it ... as the product advances towards regulatory and clinical phases. , "This is another ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com released its first ... average of 70% when buying medication online from Canadian pharmacies verified in the ... from other countries. The report (chart below) compares U.S. and foreign prices for ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in the ... which reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, ... used to remove decayed dental matter, and that teeth were then filled with bitumen, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: